BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bellanger A, Donini CF, Vendrell JA, Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy B, Bièche I, Peyruchaud O, Coll JL, Treilleux I, Maguer-Satta V, Josserand V, Cohen PA. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone. J Pathol 2017;242:73-89. [PMID: 28207159 DOI: 10.1002/path.4882] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Stradella A, Gargallo P, Cejuela M, Petit A, Bosch-Schips J, Carbonell P, Recalde S, Vethencourt A, Fernandez-Ortega A, Falo C, Gil-Gil M, Vázquez S, Obadia V, Villanueva-Vázquez R, Soler-Monsó T, Calabria I, Pernas S. Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma. Mod Pathol 2022. [PMID: 35177782 DOI: 10.1038/s41379-022-01017-7] [Reference Citation Analysis]
2 Jie Z, Xie Z, Xu W, Zhao X, Jin G, Sun X, Huang B, Tang P, Wang G, Shen S, Qin A, Fan S. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:115-25. [DOI: 10.1016/j.bbadis.2018.10.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
3 D'Oronzo S, Brown J, Coleman R. The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol 2017;9:1-9. [PMID: 28948139 DOI: 10.1016/j.jbo.2017.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
4 Josserand V, Bernard C, Michy T, Guidetti M, Vollaire J, Coll J, Hurbin A. Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis. Biomedicines 2022;10:1059. [DOI: 10.3390/biomedicines10051059] [Reference Citation Analysis]
5 Wang J, Zhou T, Wang T, Wang B. Suppression of lncRNA-ATB prevents amyloid-β-induced neurotoxicity in PC12 cells via regulating miR-200/ZNF217 axis. Biomedicine & Pharmacotherapy 2018;108:707-15. [DOI: 10.1016/j.biopha.2018.08.155] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
6 Lavaud J, Henry M, Gayet P, Fertin A, Vollaire J, Usson Y, Coll JL, Josserand V. Noninvasive monitoring of liver metastasis development via combined multispectral photoacoustic imaging and fluorescence diffuse optical tomography. Int J Biol Sci 2020;16:1616-28. [PMID: 32226306 DOI: 10.7150/ijbs.40896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Mandal CC. Osteolytic metastasis in breast cancer: effective prevention strategies. Expert Rev Anticancer Ther 2020;20:797-811. [PMID: 32772585 DOI: 10.1080/14737140.2020.1807950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Mantsou A, Pitou M, Papachristou E, Papi RM, Lamprou P, Choli-Papadopoulou T. Effect of a Bone Morphogenetic Protein-2-derived peptide on the expression of tumor marker ZNF217 in osteoblasts and MCF-7 cells. Bone Rep 2021;15:101125. [PMID: 34632002 DOI: 10.1016/j.bonr.2021.101125] [Reference Citation Analysis]
9 Hu H, Wang J, Zhou XY, Tong MT, Zhai CY, Sui XB, Zhang YH, Xie XX, Liu H, Xie JS, Pan HM, Li D. Maxillary Metastasis of Esophageal Cancer: Report of the First Case and Literature Review. Comb Chem High Throughput Screen 2018;21:801-5. [PMID: 30605052 DOI: 10.2174/1386207322666190103105938] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Rosa-Rosa JM, Caniego-Casas T, Leskela S, Cristobal E, González-Martínez S, Moreno-Moreno E, López-Miranda E, Holgado E, Pérez-Mies B, Garrido P, Palacios J. High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. Cancers (Basel) 2019;11:E74. [PMID: 30641862 DOI: 10.3390/cancers11010074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
11 Zhang X, Zhong L, Zou Z, Liang G, Tang Z, Li K, Tan S, Huang Y, Zhu X. Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases. Front Oncol 2021;11:623170. [PMID: 33816257 DOI: 10.3389/fonc.2021.623170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jiang W, Ye S, Xiang L, Yang W, He T, Pei X, Guo L, Yang H. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1). J Ovarian Res 2018;11:58. [PMID: 29986747 DOI: 10.1186/s13048-018-0429-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Bellanger A, Le DT, Vendrell J, Wierinckx A, Pongor LS, Solassol J, Lachuer J, Clezardin P, Győrffy B, Cohen PA. Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Front Oncol 2021;11:647269. [PMID: 34277402 DOI: 10.3389/fonc.2021.647269] [Reference Citation Analysis]
14 Vollaire J, Machuca-Gayet I, Lavaud J, Bellanger A, Bouazza L, El Moghrabi S, Treilleux I, Coll JL, Peyruchaud O, Josserand V, Cohen PA. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol 2019;10:667. [PMID: 31275146 DOI: 10.3389/fphar.2019.00667] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Vendrell JA, Solassol J, Győrffy B, Vilquin P, Jarlier M, Donini CF, Gamba L, Maudelonde T, Rouanet P, Cohen PA. Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer. Front Pharmacol 2018;9:1581. [PMID: 30740056 DOI: 10.3389/fphar.2018.01581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Schiano C, Soricelli A, De Nigris F, Napoli C. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions. Expert Rev Clin Immunol 2019;15:289-301. [PMID: 30570412 DOI: 10.1080/1744666X.2019.1561283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
17 Liu W, Zou J, Ren R, Liu J, Zhang G, Wang M. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma. Technol Cancer Res Treat 2021;20:1533033821992084. [PMID: 33550903 DOI: 10.1177/1533033821992084] [Reference Citation Analysis]
18 Gentile M, Centonza A, Lovero D, Palmirotta R, Porta C, Silvestris F, D'Oronzo S. Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art. J Bone Oncol 2021;26:100337. [PMID: 33240786 DOI: 10.1016/j.jbo.2020.100337] [Reference Citation Analysis]
19 Yang S, Shi F, Du Y, Wang Z, Feng Y, Song J, Liu Y, Xiao M. Long non-coding RNA CTBP1-AS2 enhances cervical cancer progression via up-regulation of ZNF217 through sponging miR-3163. Cancer Cell Int 2020;20:343. [PMID: 32742190 DOI: 10.1186/s12935-020-01430-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Wang S, Li GX, Tan CC, He R, Kang LJ, Lu JT, Li XQ, Wang QS, Liu PF, Zhai QL, Feng YM. FOXF2 reprograms breast cancer cells into bone metastasis seeds. Nat Commun 2019;10:2707. [PMID: 31222004 DOI: 10.1038/s41467-019-10379-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
21 Guerrieri AN, Montesi M, Sprio S, Laranga R, Mercatali L, Tampieri A, Donati DM, Lucarelli E. Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons. Front Bioeng Biotechnol 2020;8:589964. [PMID: 33123519 DOI: 10.3389/fbioe.2020.589964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Liu F, Ke J, Song Y. Application of Biomarkers for the Prediction and Diagnosis of Bone Metastasis in Breast Cancer. J Breast Cancer 2020;23:588-98. [PMID: 33408885 DOI: 10.4048/jbc.2020.23.e65] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Smeester BA, Draper GM, Slipek NJ, Larsson AT, Stratton N, Pomeroy EJ, Becklin KL, Yamamoto K, Williams KB, Laoharawee K, Peterson JJ, Abrahante JE, Rathe SK, Mills LJ, Crosby MR, Hudson WA, Rahrmann EP, Largaespada DA, Moriarity BS. Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma. Mol Cancer Ther 2020;19:2528-41. [PMID: 32999043 DOI: 10.1158/1535-7163.MCT-20-0369] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Wang L, Wang Y, Su B, Yu P, He J, Meng L, Xiao Q, Sun J, Zhou K, Xue Y, Tan J. Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study. Sci Rep 2020;10:16504. [PMID: 33020551 DOI: 10.1038/s41598-020-73700-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Yang CM, Chang HS, Chen HC, You JJ, Liou HH, Ting SC, Ger LP, Li SC, Tsai KW. Low C6orf141 Expression is Significantly Associated with a Poor Prognosis in Patients with Oral Cancer. Sci Rep 2019;9:4520. [PMID: 30872783 DOI: 10.1038/s41598-019-41194-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]